{"filter":{"phase":"PHASE3","status":null,"sponsor":null},"count":50,"items":[{"nct_id":"NCT07590375","brief_title":"Topical Phenytoin for Management of Gingival Recession","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"Cairo University","lead_sponsor_class":"OTHER","start_date":"2026-06-01","primary_completion_date":"2027-09-01","why_stopped":null,"last_update_date":"2026-05-15","url":"/api/v1/clinical/NCT07590375","external_url":"https://clinicaltrials.gov/study/NCT07590375"},{"nct_id":"NCT04566328","brief_title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","lead_sponsor_class":"NETWORK","start_date":"2021-02-24","primary_completion_date":"2027-12-31","why_stopped":null,"last_update_date":"2026-05-15","url":"/api/v1/clinical/NCT04566328","external_url":"https://clinicaltrials.gov/study/NCT04566328"},{"nct_id":"NCT07284654","brief_title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Vaxcyte, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2025-12-01","primary_completion_date":"2027-01","why_stopped":null,"last_update_date":"2026-05-15","url":"/api/v1/clinical/NCT07284654","external_url":"https://clinicaltrials.gov/study/NCT07284654"},{"nct_id":"NCT06456346","brief_title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2024-07-16","primary_completion_date":"2027-09-28","why_stopped":null,"last_update_date":"2026-05-15","url":"/api/v1/clinical/NCT06456346","external_url":"https://clinicaltrials.gov/study/NCT06456346"},{"nct_id":"NCT07509307","brief_title":"AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Novo Nordisk A/S","lead_sponsor_class":"INDUSTRY","start_date":"2026-04-20","primary_completion_date":"2028-08-14","why_stopped":null,"last_update_date":"2026-05-15","url":"/api/v1/clinical/NCT07509307","external_url":"https://clinicaltrials.gov/study/NCT07509307"},{"nct_id":"NCT05889390","brief_title":"Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Semmelweis University","lead_sponsor_class":"OTHER","start_date":"2023-02-20","primary_completion_date":"2025-10-31","why_stopped":null,"last_update_date":"2026-05-15","url":"/api/v1/clinical/NCT05889390","external_url":"https://clinicaltrials.gov/study/NCT05889390"},{"nct_id":"NCT07481630","brief_title":"A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Novo Nordisk A/S","lead_sponsor_class":"INDUSTRY","start_date":"2026-04-13","primary_completion_date":"2028-08-14","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT07481630","external_url":"https://clinicaltrials.gov/study/NCT07481630"},{"nct_id":"NCT05920356","brief_title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Amgen","lead_sponsor_class":"INDUSTRY","start_date":"2023-11-16","primary_completion_date":"2027-06-30","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT05920356","external_url":"https://clinicaltrials.gov/study/NCT05920356"},{"nct_id":"NCT04130997","brief_title":"An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"TG Therapeutics, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2019-11-18","primary_completion_date":"2032-05-31","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT04130997","external_url":"https://clinicaltrials.gov/study/NCT04130997"},{"nct_id":"NCT06077760","brief_title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2023-12-06","primary_completion_date":"2030-06-25","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT06077760","external_url":"https://clinicaltrials.gov/study/NCT06077760"},{"nct_id":"NCT06141473","brief_title":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Sanofi","lead_sponsor_class":"INDUSTRY","start_date":"2023-12-13","primary_completion_date":"2027-05-06","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT06141473","external_url":"https://clinicaltrials.gov/study/NCT06141473"},{"nct_id":"NCT06970847","brief_title":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Clarity Pharmaceuticals Ltd","lead_sponsor_class":"INDUSTRY","start_date":"2025-05-16","primary_completion_date":"2026-12-31","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT06970847","external_url":"https://clinicaltrials.gov/study/NCT06970847"},{"nct_id":"NCT06056830","brief_title":"Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Clarity Pharmaceuticals Ltd","lead_sponsor_class":"INDUSTRY","start_date":"2023-12-21","primary_completion_date":"2026-09","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT06056830","external_url":"https://clinicaltrials.gov/study/NCT06056830"},{"nct_id":"NCT06486142","brief_title":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Region Skane","lead_sponsor_class":"OTHER","start_date":"2022-09-21","primary_completion_date":"2028-09","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT06486142","external_url":"https://clinicaltrials.gov/study/NCT06486142"},{"nct_id":"NCT00337051","brief_title":"Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"University Hospital, Bordeaux","lead_sponsor_class":"OTHER","start_date":"2006-06","primary_completion_date":"2010-02","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT00337051","external_url":"https://clinicaltrials.gov/study/NCT00337051"},{"nct_id":"NCT01442233","brief_title":"Plasma Exchanges in Multiple Sclerosis (MS) Relapses","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"University Hospital, Bordeaux","lead_sponsor_class":"OTHER","start_date":"2012-03-08","primary_completion_date":"2017-09-21","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT01442233","external_url":"https://clinicaltrials.gov/study/NCT01442233"},{"nct_id":"NCT05916365","brief_title":"Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"Almirall, S.A.","lead_sponsor_class":"INDUSTRY","start_date":"2023-05-23","primary_completion_date":"2026-04-23","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT05916365","external_url":"https://clinicaltrials.gov/study/NCT05916365"},{"nct_id":"NCT05566795","brief_title":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Day One Biopharmaceuticals, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2023-02-27","primary_completion_date":"2027-06","why_stopped":null,"last_update_date":"2026-05-14","url":"/api/v1/clinical/NCT05566795","external_url":"https://clinicaltrials.gov/study/NCT05566795"},{"nct_id":"NCT07583446","brief_title":"Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"Seismic Pharmaceuticals Operations LLC","lead_sponsor_class":"INDUSTRY","start_date":"2026-07","primary_completion_date":"2028-12","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT07583446","external_url":"https://clinicaltrials.gov/study/NCT07583446"},{"nct_id":"NCT02829190","brief_title":"Feasibility Study of Phase-contrast MRI for Flow in the External Carotid Branches Arteries","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","lead_sponsor_class":"OTHER","start_date":"2014-01-06","primary_completion_date":"2027-12","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT02829190","external_url":"https://clinicaltrials.gov/study/NCT02829190"},{"nct_id":"NCT07582835","brief_title":"Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Cardiocentro Ticino","lead_sponsor_class":"OTHER","start_date":"2026-04-20","primary_completion_date":"2028-04","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT07582835","external_url":"https://clinicaltrials.gov/study/NCT07582835"},{"nct_id":"NCT06332534","brief_title":"Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"AbbVie","lead_sponsor_class":"INDUSTRY","start_date":"2024-08-08","primary_completion_date":"2027-06","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT06332534","external_url":"https://clinicaltrials.gov/study/NCT06332534"},{"nct_id":"NCT04759586","brief_title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"National Cancer Institute (NCI)","lead_sponsor_class":"NIH","start_date":"2021-10-05","primary_completion_date":"2026-12-31","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT04759586","external_url":"https://clinicaltrials.gov/study/NCT04759586"},{"nct_id":"NCT07071519","brief_title":"A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"AbbVie","lead_sponsor_class":"INDUSTRY","start_date":"2025-07-28","primary_completion_date":"2034-07","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT07071519","external_url":"https://clinicaltrials.gov/study/NCT07071519"},{"nct_id":"NCT06498635","brief_title":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"National Cancer Institute (NCI)","lead_sponsor_class":"NIH","start_date":"2025-04-01","primary_completion_date":"2039-07-15","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT06498635","external_url":"https://clinicaltrials.gov/study/NCT06498635"},{"nct_id":"NCT03844048","brief_title":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"AbbVie","lead_sponsor_class":"INDUSTRY","start_date":"2019-09-06","primary_completion_date":"2027-08","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT03844048","external_url":"https://clinicaltrials.gov/study/NCT03844048"},{"nct_id":"NCT06589804","brief_title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"National Cancer Institute (NCI)","lead_sponsor_class":"NIH","start_date":"2025-03-27","primary_completion_date":"2029-11-30","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT06589804","external_url":"https://clinicaltrials.gov/study/NCT06589804"},{"nct_id":"NCT04957719","brief_title":"Selatogrel Outcome Study in Suspected Acute Myocardial Infarction","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ENROLLING_BY_INVITATION","lead_sponsor_name":"Viatris Innovation GmbH","lead_sponsor_class":"INDUSTRY","start_date":"2021-08-14","primary_completion_date":"2026-12","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT04957719","external_url":"https://clinicaltrials.gov/study/NCT04957719"},{"nct_id":"NCT07095452","brief_title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"AbbVie","lead_sponsor_class":"INDUSTRY","start_date":"2026-01-08","primary_completion_date":"2042-01","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT07095452","external_url":"https://clinicaltrials.gov/study/NCT07095452"},{"nct_id":"NCT04210115","brief_title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2020-02-28","primary_completion_date":"2026-01-21","why_stopped":null,"last_update_date":"2026-05-13","url":"/api/v1/clinical/NCT04210115","external_url":"https://clinicaltrials.gov/study/NCT04210115"},{"nct_id":"NCT02262832","brief_title":"Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","lead_sponsor_class":"NIH","start_date":"2014-10-09","primary_completion_date":"2027-07-31","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT02262832","external_url":"https://clinicaltrials.gov/study/NCT02262832"},{"nct_id":"NCT06924632","brief_title":"Efficacy & Safety of Minoxidil SL Tablets in Men With AGA","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Samson Clinical Operations Pty Ltd","lead_sponsor_class":"INDUSTRY","start_date":"2025-07-14","primary_completion_date":"2026-07","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT06924632","external_url":"https://clinicaltrials.gov/study/NCT06924632"},{"nct_id":"NCT04356495","brief_title":"Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"University Hospital, Bordeaux","lead_sponsor_class":"OTHER","start_date":"2020-07-29","primary_completion_date":"2021-10-08","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT04356495","external_url":"https://clinicaltrials.gov/study/NCT04356495"},{"nct_id":"NCT04533529","brief_title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"Janssen Research & Development, LLC","lead_sponsor_class":"INDUSTRY","start_date":"2020-09-16","primary_completion_date":"2023-04-25","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT04533529","external_url":"https://clinicaltrials.gov/study/NCT04533529"},{"nct_id":"NCT07044297","brief_title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2025-07-31","primary_completion_date":"2027-07-22","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT07044297","external_url":"https://clinicaltrials.gov/study/NCT07044297"},{"nct_id":"NCT00433511","brief_title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"National Cancer Institute (NCI)","lead_sponsor_class":"NIH","start_date":"2007-11-02","primary_completion_date":"2014-01-07","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT00433511","external_url":"https://clinicaltrials.gov/study/NCT00433511"},{"nct_id":"NCT06096116","brief_title":"Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Octapharma","lead_sponsor_class":"INDUSTRY","start_date":"2024-08-21","primary_completion_date":"2028-03","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT06096116","external_url":"https://clinicaltrials.gov/study/NCT06096116"},{"nct_id":"NCT06890598","brief_title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Eli Lilly and Company","lead_sponsor_class":"INDUSTRY","start_date":"2025-03-27","primary_completion_date":"2029-05","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT06890598","external_url":"https://clinicaltrials.gov/study/NCT06890598"},{"nct_id":"NCT05980949","brief_title":"Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","lead_sponsor_class":"INDUSTRY","start_date":"2023-07-11","primary_completion_date":"2027-09-07","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT05980949","external_url":"https://clinicaltrials.gov/study/NCT05980949"},{"nct_id":"NCT06568484","brief_title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Johns Hopkins University","lead_sponsor_class":"OTHER","start_date":"2026-05-08","primary_completion_date":"2027-07","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT06568484","external_url":"https://clinicaltrials.gov/study/NCT06568484"},{"nct_id":"NCT06948214","brief_title":"Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Lumos Pharma","lead_sponsor_class":"INDUSTRY","start_date":"2026-04","primary_completion_date":"2027-12","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT06948214","external_url":"https://clinicaltrials.gov/study/NCT06948214"},{"nct_id":"NCT07266831","brief_title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2025-12-18","primary_completion_date":"2029-03-21","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT07266831","external_url":"https://clinicaltrials.gov/study/NCT07266831"},{"nct_id":"NCT07220252","brief_title":"Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis","phase":"PHASE2,PHASE3","study_type":"INTERVENTIONAL","overall_status":"NOT_YET_RECRUITING","lead_sponsor_name":"TG Therapeutics, Inc.","lead_sponsor_class":"INDUSTRY","start_date":"2026-06-01","primary_completion_date":"2030-01-01","why_stopped":null,"last_update_date":"2026-05-12","url":"/api/v1/clinical/NCT07220252","external_url":"https://clinicaltrials.gov/study/NCT07220252"},{"nct_id":"NCT04641338","brief_title":"Fixed Combination of Dipyrone and Codeine for Controlling Pain After Pelvic-abdominal Surgery","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"COMPLETED","lead_sponsor_name":"Brazilian Clinical Research Institute","lead_sponsor_class":"OTHER","start_date":"2023-03-16","primary_completion_date":"2024-03-15","why_stopped":null,"last_update_date":"2026-05-11","url":"/api/v1/clinical/NCT04641338","external_url":"https://clinicaltrials.gov/study/NCT04641338"},{"nct_id":"NCT06646276","brief_title":"A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Bristol-Myers Squibb","lead_sponsor_class":"INDUSTRY","start_date":"2025-02-25","primary_completion_date":"2028-04-06","why_stopped":null,"last_update_date":"2026-05-11","url":"/api/v1/clinical/NCT06646276","external_url":"https://clinicaltrials.gov/study/NCT06646276"},{"nct_id":"NCT05156398","brief_title":"Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Pfizer","lead_sponsor_class":"INDUSTRY","start_date":"2022-02-28","primary_completion_date":"2031-11-29","why_stopped":null,"last_update_date":"2026-05-11","url":"/api/v1/clinical/NCT05156398","external_url":"https://clinicaltrials.gov/study/NCT05156398"},{"nct_id":"NCT04251533","brief_title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"TERMINATED","lead_sponsor_name":"Novartis Pharmaceuticals","lead_sponsor_class":"INDUSTRY","start_date":"2020-06-08","primary_completion_date":"2023-05-31","why_stopped":"The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.","last_update_date":"2026-05-11","url":"/api/v1/clinical/NCT04251533","external_url":"https://clinicaltrials.gov/study/NCT04251533"},{"nct_id":"NCT01604135","brief_title":"Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"ACTIVE_NOT_RECRUITING","lead_sponsor_name":"Sahlgrenska University Hospital","lead_sponsor_class":"OTHER","start_date":"2012-05","primary_completion_date":"2027-04","why_stopped":null,"last_update_date":"2026-05-11","url":"/api/v1/clinical/NCT01604135","external_url":"https://clinicaltrials.gov/study/NCT01604135"},{"nct_id":"NCT06846671","brief_title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"BeOne Medicines","lead_sponsor_class":"INDUSTRY","start_date":"2025-04-10","primary_completion_date":"2028-05-15","why_stopped":null,"last_update_date":"2026-05-11","url":"/api/v1/clinical/NCT06846671","external_url":"https://clinicaltrials.gov/study/NCT06846671"},{"nct_id":"NCT05947851","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","phase":"PHASE3","study_type":"INTERVENTIONAL","overall_status":"RECRUITING","lead_sponsor_name":"Merck Sharp & Dohme LLC","lead_sponsor_class":"INDUSTRY","start_date":"2023-08-08","primary_completion_date":"2032-06-01","why_stopped":null,"last_update_date":"2026-05-11","url":"/api/v1/clinical/NCT05947851","external_url":"https://clinicaltrials.gov/study/NCT05947851"}]}